Psoriatic Arthritis and Psoriasis Treatment Decision Aid

Clinical Trial ID: NCT03737045

Description

The purpose of this study is to create and test a patient decision aid that facilitates the shared decision-making process when patients with psoriasis and/or psoriatic arthritis are starting or switching to a new therapy.

Prior to the interventional study, we will develop a decision aid using design thinking. In this interventional study, we will implement and test a patient-centered decision aid for therapy selection among patients with psoriasis and/or psoriatic arthritis who are starting or switching to a new medication.


Criteria

Inclusion Criteria: 1. Age 18 years or older 2. Diagnosis of psoriasis (as confirmed by dermatologist) or psoriatic arthritis (as confirmed by rheumatologist) 3. Treated at Penn In addition to the above, for the observation and implementation phases of the study: 4. Initiation of a new psoriasis or psoriatic arthritis treatment - Biosimilars that have been approved by the FDA and available on the US market will similarly be eligible for participation - Patients may be taking other traditional DMARDs. - A washout period is not required. Exclusion Criteria: 1. Unable to give informed consent 2. Youth, under the age of 18 years 3. Patients without psoriasis or psoriatic arthritis 4. Not being treated at a Penn clinic In addition to the above, for the observation and implementation phases of the study: 5. Not starting or switching to a new medication

  • Start Date

    2018-12-01

  • Last Updated

    2019-02-05

  • Sponsor

    Pfizer

  • Condition Name

    Psoriasis

Learn about this trial.

Check the eligibility requirements, study details, and more.

Related Trials

Different trials target different symptoms, condition types, and patients. Learn more about other emergeing treatments being investigated now.